Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Pfizer, AstraZeneca, Glaxo, Sanofi's and Eli Lilly

Read MoreHide Full Article

For Immediate Release

Chicago, IL – February 14, 2022 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Pfizer (PFE - Free Report) , AstraZeneca (AZN - Free Report) , Glaxo (GSK - Free Report) ,Sanofi’s (SNY - Free Report) and  Eli Lilly (LLY - Free Report) .

Here are highlights from Friday’s Analyst Blog:

Pharma Stock Roundup: Q4 Earnings Edition

This week, Pfizer, AstraZeneca andGlaxo announced fourth-quarter and full-year 2021 results. While the FDA approved Sanofi’s new rare blood disorder medicine, Enjaymo, an FDA advisory committee, voted that Eli Lilly and partner Innovent Biologics conduct an additional study to get approval for their lung cancer candidate, sintilimab, in the United States.

Recap of the Week’s Most Important Stories

Earnings Update:Pfizer’s fourth-quarter results were mixed as it beat estimates for earnings but missed the same for sales. Direct sales and alliance revenues from it and partner BioNTech’s COVID-19 vaccine, Comirnaty, were $12.5 billion in the quarter,

Pfizer issued its financial guidance for 2022. Revenues are expected in the range of $98.0 billion to $102.0 billion. The revenue guidance includes approximately $32.0 billion in sales from Comirnaty and $22 billion from a new promising oral antiviral pill for COVID-19, Paxlovid. Adjusted earnings per share are expected to be in a range of $6.35 to $6.55. Its sales guidance for 2022 was below market expectations.

Glaxo beat estimates for both earnings and sales. While Pharmaceuticals sales were up 25% at CER, sales in the Consumer Healthcare segment increased 10%. Vaccine sales declined 7% at CER due to lower revenues from the majority of its vaccines, including Shingrix. Glaxo announced its earnings growth expectations for the year for the new company to be formed after the demerger of the Consumer Healthcare business. The company expects sales of the new Glaxo to increase 5% to 7% in 2022

AstraZeneca’s fourth-quarter results were strong as it beat estimates for both earnings and sales. Product sales growth was driven by its COVID-19 vaccine and higher sales of newer medicines across Oncology and CVRM units like Tagrisso and Farxiga, which offset some negative impacts from the pandemic and slower sales growth in China. The rare disease drugs added following the Alexion acquisition also aided sales growth.

AstraZeneca also issued encouraging guidance for 2022. It expects total revenues to increase in high-teens percentage in 2022.

FDA Approves Sanofi’s New Rare Blood Disorder Drug: The FDA granted approval to Sanofi’s Enjaymo (sutimlimab-jome) for the treatment of hemolysis in adult patients with cold agglutinin disease (CAD), a rare blood disorder. Enjaymo is now the first and only FDA- approved therapy for treating patients with CAD. Regulatory applications seeking approval for sutimlimab in Europe and Japan are currently under review.

In November last year, the FDA had issued a complete response letter (CRL) to the biologics license application (BLA) for sutimlimab due to certain deficiencies identified by the FDA during a pre-license inspection of a third-party manufacturing facility. Finally, the FDA accepted the resubmission of the BLA for sutimlimab in October 2021. 

The FDA accepted and granted priority review to Sanofi’s supplemental biologics license application (sBLA) seeking approval for its blockbuster drug Dupixent for treating moderate-to-severe atopic dermatitis in children aged 6 months to 5 years. The FDA’s decision is expected on Jun 9, 2022. Presently, Dupixent is approved to treat moderate-to-severe atopic dermatitis in patients 6 years and older.

FDA Panel Votes Against Approving Lilly’s Sintilimab BLA:The FDA’s Oncologic Drugs Advisory Committee voted 14-0 that Lilly and partner Innovent Biologics conduct an additional trial for seeking approval of their lung cancer candidate, sintilimab

Lilly/Innovent market sintilimab with the trade name of Tyvyt only in China. Lilly is seeking approval for sintilimab in the United States for the first-line treatment of adult patients with advanced non-squamous non-small cell lung cancer (NSCLC).

The ODAC committee’s negative vote stemmed from the fact that the BLA for sintilimab, which was submitted by Innovent, was based on a study, ORIENT-11, conducted exclusively in China. The committee argued that the data from the study are not applicable to the U.S. population and U.S. medical practice. It is difficult to make a definitive conclusion if the pharmacokinetics (PK) data can be applied to the diverse U.S population.

The committee thus recommended an additional study to demonstrate applicability to the U.S. population before the BLA can be approved. Lilly and Innovent stated their disappointment with the ODAC outcome and will work with the FDA to complete the review of the sintilimab application.

Lilly also announced an agreement to supply the U.S. government up to 600,000 doses of its investigational COVID drug bebtelovimab for at least $720 million, if granted emergency approval by the FDA. Lilly has filed an application seeking emergency approval for bebtelovimab for mild-to-moderate COVID-19.

In January, the FDA revised the emergency use authorization (EUA) for Lilly’s already approved antibody cocktail medicine for COVID-19, bamlanivimab plus etesevimab, limiting their use in patients who have been infected or exposed to a coronavirus variant that is susceptible to these treatments.

The FDA’s decision to limit the authorized use of bamlanivimab/etesevimab was based on data, which showed that these treatment options are highly unlikely to be effective against the Omicron variant in the United States. However, Lilly said that an authentic virus analysis of bebtelovimab demonstrated that bebtelovimab neutralizes all known variants of concern, including Omicron.

The NYSE ARCA Pharmaceutical Index declined 0.9% in the last five trading sessions.

In the last five trading sessions, AbbVie rose the most (2.2%) while Pfizer declined the most (5.2%).

In the past six months, AbbVie has recorded the maximum gain (26.2%) while Lilly declined the most (8.8%)

(See the last pharma stock roundup here: MRK, LLY, ABBV Post Q4 Earnings, PFE Ends Vupanorsen Program)

What's Next in the Pharma World?

Watch out for regular pipeline and regulatory updates next week.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know about our 10 top picks for the entirety of 2022?

From inception in 2012 through 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% versus the S&P 500’s +348.7%. Now our Director of Research has combed through 4,000 companies covered by the Zacks Rank and has handpicked the best 10 tickers to buy and hold. Don’t miss your chance to get in…because the sooner you do, the more upside you stand to grab.

See Stocks Now >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                                 

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.